Despite acquired resistance to standard anti-androgen therapy with bicalutamide, tumor growth continues to depend on the androgen receptor (AR), suggesting that AR inhibitors of increased potency may have efficacy in castration-resistant prostate cancer (CRPC). BMS-641988 is a novel AR antagonist that has a 20-fold higher binding affinity to AR, and between 3-and 7-fold greater potency as an antagonist of AR-mediated transcription in cell-based reporter assays, compared with bicalutamide. As a result of promising preclinical activity, BMS-641988 was evaluated in this multi-institutional phase 1 study for men with CRPC. In the setting of an episode of seizure attributable to the study drug, and limited anti-tumor activity in part due to counteragonism, further development of BMS-641988 was stopped in favor of exploring second generation antiandrogens which focus on preventing translocation of AR into the nucleus and retain antagonism in the setting of increased AR. Experimental Design: Doses were escalated from 5 to 150 mg based on discrete pharmacokinetic parameters in cohorts of 3 to 6 subjects. After establishing safety with 20 mg of BMS-641988 in the United States, a companion study was opened in Japan to assess differences in drug metabolism between populations.
INTRODUCTION
The initial responses of prostate cancers to therapies that deplete or block androgen action are among the most dramatic in clinical oncology. These responses are not durable and over time virtually all tumors progress to a castration-resistant state that is manifest by a range of clinical phenotypes, but at a molecular level show evidence of reactivation and continued dependence on androgen receptor (AR) signaling for growth (1) . Consequently, the AR remains an important therapeutic target. BMS-641988 is a novel AR antagonist that has a 20-fold higher binding affinity to AR, and between 3-and 7-fold greater potency as an antagonist of AR-mediated transcription in cell-based reporter assays, compared with the most widely used anti-androgen, bicalutamide (2) .
In preclinical studies, BMS-641988 inhibits the growth of CWR-22-BMSLD1 human prostate xenografts, which have a mutant AR (3) . These tumors are sensitive to castration but are only marginally sensitive to bicalutamide. BMS-641988 also stabilizes tumors that are progressing on bicalutamide (P<0.05), although the tumors regrow upon discontinuation of treatment, which is consistent with a cytostatic as opposed to cytocidal effect (2) . Both BMS-641988 and bicalutamide are active against LuCap 23.1 prostate cancer xenografts, which possess amplified expression of wild-type AR (4), although BMS-641988 is more potent (2) . The downstream effects on transcriptional and proteomic profiles are indicative of a blockade of androgen-driven signalling, more similar to castration than bicalutamide treatment.
In vitro experiments show that the enzyme cytochrome P450 3A4 (CYP3A4) converts BMS-641988 to BMS-570511, which is in turn reduced to BMS-501949 by cytosolic reductases. All three compounds antagonize AR-dependent transcription, function as AR antagonists in rats, and show equipotent growth-inhibitory effects against CWR-22 xenografts (data not shown). Notably, in the most sensitive dog species, seizures were observed with BMS-501949 at doses of 25 mg/kg corresponding to exposures of 1010 uM*hr as defined by the area under the concentration-time curve from 0 to 24 hours without detectable metastases. The criteria for rising PSA required a minimum of 3 measurements obtained more than 1 week apart, with the last value >5 ng/mL (5).
The pre-study evaluation included a history and physical examination, complete blood and platelet count, chemistry panel, PSA level, and electrocardiogram (ECG). Imaging for metastatic disease included a radionuclide bone scan and either computed tomography (CT) or magnetic resonance imaging (MRI) of the brain, chest, abdomen, and pelvis. Patients with a history of significant cardiac disease or a seizure disorder were excluded.
BMS-641988 was administered orally under fasting conditions. The starting dose in the US study was 5 mg per day, and subsequent dosages were 10, 20, 40, 60, 100, and 150 mg per day. In the companion Japanese study, the starting dose was 20 mg.
Beginning with the 40 mg cohort, the first two patients of each group in the US were randomized in a 1:1 ratio and in a double-blinded fashion to receive a single dose of BMS-641988 or placebo on Cycle 1, Day 1 (Cycles defined as 28 days), to evaluate single-dose PK and the QTc interval. Assuming acceptable safety results, both patients subsequently received BMS-641988 continuously on a daily schedule starting on Cycle 1, Day 8, and four additional patients were enrolled at the same dosage. These additional patients were not randomized but had single-dose PK sampling and a 7-day washout before continuous daily dosing. All patients were observed for 28 days to insure safety before the next higher dose level was opened for enrollment. At least 3 to 6 patients were treated at each dose level, provided no DLTs occurred; and for the purposes of acquiring additional safety and efficacy data, an additional number of participants could have been enrolled at any dose level that had no DLT. The plasma concentration-time data for BMS-641988, BMS-501949, and BMS-570511
were analyzed by the non-compartmental method using Kinetica Version 4.4.1 (Thermo Electron Corporation, Philadelphia, Pennsylvania, USA). The PK parameters assessed included maximum observed concentration (C max ), time of maximum observed
Safety and Tolerability
Adverse events regardless of causality are shown in Table 2 . Overall, the most frequent adverse events were fatigue (25%) and gastrointestinal events (31%), all of which were grade 1 or 2. Most notable was a grade 3 epilepsy event that occurred in a patient receiving 60 mg BMS-641988 in Japan. After two daily doses of BMS-641988, the patient lost consciousness with "loud sneezing," drooling, and hypertension. These symptoms were witnessed by medical personnel and resolved within 30 minutes without intervention. A neurologist who assessed the patient 5 minutes after recovery reported that the clinical findings were unclear but that the electroencephalogram findings were partially abnormal. No acute findings were detected by MRI with contrast. The study drug was discontinued due to the event and subsequently a decision was made to end the trial. PK analysis for this patient is not available.
Pharmacokinetics
The plasma concentrations of BMS-641988 and its active metabolites, BMS-570511
and BMS-501949, were proportional to dose in the dosage range of 5 to 100 mg ( Figure   1 ). At all dose levels, concentrations of BMS-641988, BMS-570511, and BMS-501949 remained well below the BMS-501949 NOAEL associated with seizures in preclinical dog models. At doses of 60 mg and higher, the sum of the active metabolites BMS- (Table 3A) . PK results were similar for the Japanese patients based on a smaller patient cohort (Table 3B) .
Anti-tumor Effects
PSA. A waterfall plot of the maximum percentage change in PSA levels from baseline of the 61 assessable patients is presented in Figure 2 . Overall, 10 of 61 patients (16%)
had a ≥30% decline in PSA and all were chemotherapy naive. None of the 16 patients with prior exposure to chemotherapy had a PSA decline of ≥30%. n, number of subjects; AE, adverse events.
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